Parkinson's Disease

The potential of nilotinib in the treatment of movement disorders 6:36
The potential of nilotinib in the treatment of movement disorders
Charbel Moussa • 28 Nov 2022
Updates on α-synuclein as a biomarker in Parkinson’s disease 1:10
Updates on α-synuclein as a biomarker in Parkinson’s disease
Gennaro Pagano • 17 Sep 2022
Development of novel trial outcomes in Parkinson’s disease 1:42
Development of novel trial outcomes in Parkinson’s disease
Gennaro Pagano • 17 Sep 2022
Tackling sleep disturbances in Parkinson’s disease 1:33
Tackling sleep disturbances in Parkinson’s disease
Gennaro Pagano • 17 Sep 2022
Prodromal Parkinson’s disease: identification & ethical issues 1:09
Prodromal Parkinson’s disease: identification & ethical issues
Gennaro Pagano • 17 Sep 2022
Systems underlying music-induced paradoxical movement in Parkinson’s disease 3:36
Systems underlying music-induced paradoxical movement in Parkinson’s disease
Bin Hu • 12 Sep 2022
Effects of apomorphine sublingual film on QT interval in patients with Parkinson’s disease 0:53
Effects of apomorphine sublingual film on QT interval in patients with Parkinson’s disease
Fabrizio Stocchi • 16 Sep 2022
Implementing device-aided treatment strategies in advanced Parkinson’s disease 1:04
Implementing device-aided treatment strategies in advanced Parkinson’s disease
Eric Freire-Alvarez • 15 Sep 2022
Subcutaneous levodopa/carbidopa infusion for Parkinson’s disease 0:50
Subcutaneous levodopa/carbidopa infusion for Parkinson’s disease
Eric Freire-Alvarez • 15 Sep 2022
Targeting α-synuclein & neuroinflammation in Parkinson’s disease 1:26
Targeting α-synuclein & neuroinflammation in Parkinson’s disease
Fabrizio Stocchi • 16 Sep 2022
In-home remote assessment of the MDS-UPDRS Part III: development a guide for patients 5:23
In-home remote assessment of the MDS-UPDRS Part III: development a guide for patients
Michelle Tosin • 23 Sep 2022
Understanding patient perceptions of medication adherence in PD 4:22
Understanding patient perceptions of medication adherence in PD
Michelle Tosin • 23 Sep 2022
α-synuclein & Parkinson’s disease: moving away from anti-α-synuclein approaches? 2:47
α-synuclein & Parkinson’s disease: moving away from anti-α-synuclein approaches?
Alberto Espay • 16 Sep 2022
New MDS task force on early-onset Parkinson’s disease 5:15
New MDS task force on early-onset Parkinson’s disease
Rodolfo Savica • 16 Sep 2022
Continuous dopaminergic stimulation: Advanced treatments in Parkinson’s disease 1:14
Continuous dopaminergic stimulation: Advanced treatments in Parkinson’s disease
Per Odin • 17 Sep 2022
Quality of life in patients with late-stage Parkinson’s disease 1:39
Quality of life in patients with late-stage Parkinson’s disease
Per Odin • 17 Sep 2022
The content of VJNeurology is intended for healthcare professionals